Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
July 14, 2015
Assignees:
Societe Diagnostica-Stago, Assistance Publique-Hopitaux de Paris
Inventors:
Bibi Shah Soltan Mirshahi, Jeannette Soria
Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.
Type:
Grant
Filed:
February 25, 2003
Date of Patent:
November 11, 2014
Assignees:
Societe Diagnostica-Stago, Assistance Publique-Hopitaux de Paris
Inventors:
Bibi Shah Soltan Mirshahi, Jeannette Soria
Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.
Type:
Application
Filed:
September 23, 2011
Publication date:
March 22, 2012
Applicants:
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, SOCIETE DIAGNOSTICA-STAGO
Inventors:
Bibi Shah Soltan Mirshahi, Jeannette Soria
Abstract: The invention concerns contact activators for the endogenous coagulation pathway and their use in exploring coagulation anomalies. The activators of the invention are derivatives of gallic acid, preferably polyethylene glycol gallates.
Abstract: The invention relates to chromogenic compounds and the use thereof for the determination of enzymes of the family of carboxypeptidases N and carboxypeptidases U. The above is more specifically a compound of formula (I) in which A=(1), (2), (3), (4) or (5). R1. R2=H. —CH3, —CH(CH3)2, —OCH3, —Cl.—CF3,—OCF3,—SCH3, R3=an amino acid group which may be hydrolysed by a carboxypeptidase A and R4=a basic amino acid group.
Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.
Type:
Application
Filed:
February 25, 2003
Publication date:
September 18, 2003
Applicant:
Societe Diagnostica-Stago
Inventors:
Bibi Shah Soltan Mirshahi, Jeannette Soria
Abstract: A process for determining a resistance to activated protein C of a test specimen of human plasma following the steps of: (1) mixing together (a) the test specimen of human plasma, (b) a reactant deficient in factor V which supplies at least most of the coagulation factors other than factor V, and (c) the venom of Crotalus viridis helleri which specifically activates factor X to Xa, and incubating the mixture of (a), (b) and (c) for at least one minute at a temperature of between 10 and 45° C.; (2) introducing into the incubated mixture(i) Ca2+ or (ii) Ca2++exogenic activated protein C; and (3) determining the coagulation time (i) in the absence of activated protein C and (ii) in the presence of activated protein C. Steps (1) to (3) are repeated, but replacing, in step (1), the test specimen with a normal plasma as control and correlating resistance to activated protein C by comparing the determinations made in steps for the test specimen and for the normal plasma.